Abstract
Introduction/BackgroundIn PAOLA-1/ENGOT-ov25 (NCT02477644), maintenance PARP inhibitor (PARPi) olaparib+bevacizumab improved progression-free survival (PFS) in patients with homologous recombination-deficient (HRD+) advanced ovarian cancer (Ray-Coquard. NEJM 2019;381:2416–28). Post-hoc analysis showed the efficacy of...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have